Vitamin D and Multiple Sclerosis
Clinical Neuroimmunology pp 197-212
Part of the Current Clinical Neurology book series (CCNEU)
Michael J. BradshawMichael F. Holick James M. Stankiewicz
Dr. Holick (a co-author) was very impressed during va isit to Dr. Coimbra in Brazil about 5 years ago
Dr. Coiumbra's great success with >150 ng of vitamin D is not mentioned here
Perhaps because no clinical trials are involved.
This chapter recommends only 40-70 ng of vitamin D
This chapter does not appear to mention the extremely important cofactors - such as Magnesium
Multiple Sclerosis and (lots of) Vitamin D - book by patient on Coimbra protocol - Feb 2016 contains protocol description
Vitamin D Protocol used by Dr. Coimbra for Multiple Sclerosis etc.
Snips as of April 2016 http://www.vitamindprotocol.com/dr.-coimbra-s-ms-protocol.html
- 1,000 IU's vitamin D per kilogram as a first approximation
(apparently increased/decreased depending of resulting vitamin D blood level) - Vitamin B2, magnesium glycinate, boron, chromium picolinate, Omega 3 DHA, Zinc, Methylcobalamin form of B12, Choline, etc.
- Lack of B12 may affect 10%–15% of the general population and may be the most prevalent genetic risk factor for several human diseases
- Discontinue eating or drinking dairy products or calcium enriched foods or beverages, also no Ca supplements
- Drink as least 2.5 liters [85 ounces] of fluids, preferably water
- Required Tests: Vitamin D, Parathyroid, Blood calcium, urinary calcium
Download the PDF from Sci-Hub via Vitamin D Life
Table of Contents
Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system. Much has been learned about the role of vitamin D in MS, although our understanding remains incomplete. While the precise etiology of MS remains incompletely understood, low vitamin D status is one factor that appears to predispose to the development of MS, and patients with low 25(OH)D levels may be at greater risk of disease activity. Clinical trials are currently underway to more directly address the role of vitamin D supplementation in MS, yet further investigations are needed. This chapter reviews the role of vitamin D in the pathophysiology of MS and the evidence related to clinical outcomes in patients with MS who have vitamin D deficiency.